ArticleInternational journal of clinical and experimental medicine2015
Expression of HAX1 and Ki-67 in breast cancer and its correlations with patient's clinicopathological characteristics and prognosis.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- MitomiRs as Key Players in Metabolic Reprogramming of Blood Cell Development.Experientia supplementum (2012) · 2026Review
- Biophysical and NMR analysis reveals binding affinity between HAX1 and CLPB proteins.Magnetic resonance letters · 2025Article
- Hax1 regulate focal adhesion dynamics through IQGAP1.Cell communication and signaling : CCS · 2023Article
- Extracellular vesicles rich in HAX1 promote angiogenesis by modulating ITGB6 translation.Journal of extracellular vesicles · 2022Article
- Mitochondrial microRNA (MitomiRs) in cancer and complex mitochondrial diseases: current status and future perspectives.Cellular and molecular life sciences : CMLS · 2021Review
- The interactome of multifunctional HAX1 protein suggests its role in the regulation of energy metabolism, de-aggregation, cytoskeleton organization and RNA-processing.Bioscience reports · 2020Article
- MicroRNA‑125a‑5p regulates liver cancer cell growth, migration and invasion and EMT by targeting HAX1.International journal of molecular medicine · 2020Article
- HAX1 impact on collective cell migration, cell adhesion, and cell shape is linked to the regulation of actomyosin contractility.Molecular biology of the cell · 2019Article
- Cytoplasmic HAX1 Is an Independent Risk Factor for Breast Cancer Metastasis.Journal of oncology · 2019Article
- Abnormal expression of HAX‑1 is associated with cellular proliferation and migration in human hypopharyngeal squamous cell carcinoma.Molecular medicine reports · 2017Article
- MicroRNA-223 Increases the Sensitivity of Triple-Negative Breast Cancer Stem Cells to TRAIL-Induced Apoptosis by Targeting HAX-1.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the HS-1-associated protein X-1 (HAX1) and Ki-67 expression in the breast cancer and its clinical significance.
methodsBreast cancer tissues and tumor-adjacent tissues were collected from 81 patients, and immunohistochemistry was conducted to detect the HAX1 and Ki-67 expression. The correlations of HAX1 expression with demographics, clinicopathological characteristics and prognosis were evaluated.
resultsHAX1 was highly expressed in the breast cancer, and its expression was related to the degree of breast cancer differentiation (P=0.002), lymph nodes metastasis (P=0.008) and progesterone receptor (PR) (P=0.021), but not with the age, tumor size, histological type, estrogen receptor (ER), HER2 and p53. HAX1 expression was positively related to Ki-67 expression in the breast cancer (r(2)=0.394, P=0.019). In addition, a higher HAX-1 expression was related to a lower 10-year survival rate.
conclusionHAX1 is a new protein related to the breast cancer and probably plays an important role in the invasion and metastasis of breast cancer. Thus, HAX1 may be used as a potential target for the therapy of breast cancer.
Indexed as
Identifiers
26885017PMC4723862W2281168026What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.